Phagenesis, a Manchester, UK-based company which has developed a neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing.

英国曼彻斯特的一家公司Phagenesis开发了一种治疗吞咽功能障碍的神经刺激系统，已完成4200万美元的D系列融资。

The round was led by EQT Life Sciences and Sectoral Asset Management with participation from with new investors British Patient Capital, Northern Gritstone and Aphelion.

本轮投资由EQT生命科学和部门资产管理公司牵头，新投资者英国患者资本、北方砂砾石和Aphelion也参与了此次投资。

The company intends to use the funds to expand operations and development efforts. With the recent approval of Phagenyx® by the FDA in the United States, the investment is primarily intended to support commercialization in the United States and deepen penetration in Europe. It will also support clinical trials, regulatory activities, as well as research and development of pipeline products.

该公司打算利用这些资金扩大运营和开发工作。随着美国FDA最近批准Phagnyx®，该投资主要用于支持美国的商业化并加深在欧洲的渗透。它还将支持临床试验、监管活动以及管道产品的研究和开发。

Co-founded by Dr. Conor Mulrooney and Professor Shaheen Hamdy from the University of Manchester in 2007, and led by Reinhard Krickl, CEO, Phagenesis offers innovative treatments for neurogenic dysphagia using pharyngeal electrical stimulation, PES. The Phagenyx® Neurostimulation System targets and restores the neurological components of swallowing coordination and control that are disrupted due to brain injury (including stroke) or because of prolonged mechanical ventilation.

2007年，由曼彻斯特大学的Conor Mulrooney博士和Shaheen Hamdy教授共同创立，由首席执行官Reinhard Krickl领导，Phagenesis通过咽部电刺激（PES）提供神经源性吞咽困难的创新治疗方法。Phagenyx®神经刺激系统针对并恢复吞咽协调和控制的神经系统成分，这些神经系统成分因脑损伤（包括中风）或长期机械通气而被破坏。

Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva. Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.

吞咽功能障碍（吞咽困难）患者无法安全或有效地进食，饮水或管理自己的唾液。吞咽困难通常会导致危及生命的并发症，如肺炎，并且还会导致医疗费用大幅增加。

Commenting on the news, Reinhard Krickl said: “We will invest in exceptional talent to scale up our customer outreach and to support passionate clinicians who want to bring our therapy to those who need it. Our novel and proven therapy can help the millions of patients every year who suffer from swallowing disorders.”

莱因哈德·克里克尔（ReinhardKrickl）在评论这条新闻时表示：“我们将投资非凡的人才，扩大我们的客户推广范围，并支持热情的临床医生，他们希望将我们的治疗方法带给需要的人。我们新颖且经验证的治疗方法可以帮助每年数百万患有吞咽障碍的患者。”